Reunion Neuroscience

Reunion is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds. $REUN

[Reunion Neuroscience @ReunionNeuro]

We are thrilled to share our recent article in Patient Safety & Quality Healthcare with Sheryl Kingsberg, PhD, discussing the importance of bringing attention to what is #postpartumdepression, and the treatment efforts being made to help in this area of great unmet medical need with our ongoing RECONNECT Phase 2 trial (https://t.co/VxKspDuXdw).
Read full article here: https://t.co/SfI1pJGfVc

[Reunion Neuroscience @ReunionNeuro]

We are excited to share our recent article in Contemporary OB/GYN featuring Sheryl Kingsberg, PhD, discussing our ongoing RECONNECT Phase 2 trial (https://t.co/VxKspDuXdw) to help bring a single dose #pyschedelic
treatment to women suffering from moderate to severe #postpartumdepression.
Read full article here: https://t.co/316NLExOwY

[Reunion Neuroscience @ReunionNeuro]

We are proud to acknowledge today as #WorldMentalHealthDay, a global initiative to raise awareness and break the stigma around mental health. This initiative underscores our mission at #ReunionNeuroscience to advance next-generation therapies that address mental health conditions and improve the lives of patients and families impacted by the growing mental health crisis. To support this mission, we are currently enrolling patients in our RECONNECT Phase 2 trial evaluating our lead candidate RE104 for the treatment of moderate to severe postpartum depression. To learn more about the RECONNECT trial and patient eligibility, please visit: https://t.co/VxKspDuXdw

[Reunion Neuroscience @ReunionNeuro]

Today we announced a new partnership with the Seleni Institute, a nonprofit organization that provides treatment and training for #maternalmentalhealth and wellness issues. This partnership furthers Reunion’s commitment to developing our lead psychedelic investigational product, RE104, for women suffering from moderate to severe #postpartumdepression through our RECONNECT Phase 2 trial. To learn more about the trial and its eligibility requirements, please visit: https://t.co/VxKspDuXdw. To learn more about Seleni and to apply to the scholarship program, please visit: https://t.co/s8TxuJMyhD.

[Reunion Neuroscience @ReunionNeuro]

Our President and CEO, @gtmayes was featured in the @WSJ discussing @ReunionNeuro $103 million Series A financing for our ongoing RECONNECT Phase 2 trial (https://t.co/VxKspDuXdw) to help bring a novel treatment to women suffering from moderate to severe postpartum depression.
Read full article here: https://t.co/HElt5HHahu

[Reunion Neuroscience @ReunionNeuro]

Today is National Women’s Health and Fitness Day, a day to celebrate the importance of promoting health awareness and fitness for all women, including new mothers. @ReunionNeuro is committed to developing a single dose treatment option for women suffering from moderate to severe postpartum depression through its RECONNECT Phase 2 trial that offers eligible women the opportunity to evaluate the safety and efficacy of a next-generation psychedelic molecule. To learn more about the RECONNECT trial, please visit: https://t.co/VxKspDuXdw

[Reunion Neuroscience @ReunionNeuro]

We are pleased to welcome Mark Pollack, M.D. as our new Chief Medical Officer at @ReunionNeuro. With over nearly four decades of experience in neuroscientific research and pharmaceutical development, Dr. Pollack brings a wealth of knowledge and leadership to Reunion at a pivotal time as we advance the RECONNECT Phase 2 trial, continuing our mission to deliver therapies for patients with mental health disorders. To learn more about the RECONNECT trial, please visit: https://t.co/VxKspDuXdw

[Reunion Neuroscience @ReunionNeuro]

Today we announced a new partnership with “Is Mom OK?” in recognition of #maternalsuicidepreventionmonth. This unprecedented initiative, launched by @CherishedMomOrg, a renowned nonprofit organization dedicated to transforming the landscape of #maternalmentalhealth, aims to educate and drive support for moms, with a specific focus on addressing maternal suicide and mortality. This partnership furthers our commitment to patients and families suffering from postpartum depression and follows the recent initiation of the RECONNECT Phase 2 trial that evaluates our lead molecule RE104 in mothers with moderate to severe postpartum depression. To learn more about the study, please visit: https://t.co/VxKspDuXdw

[Reunion Neuroscience @ReunionNeuro]

We are pleased to announce that the first patient has been dosed in our RECONNECT Phase 2 clinical trial of RE104 for the treatment of #postpartumdepression. This marks a significant clinical milestone in the development of our novel, fast-acting, single-dose, #psychedelic therapies to address underserved #mentalhealthdisorders. Learn more: https://t.co/NSOlyWzAFc

[Reunion Neuroscience @ReunionNeuro]

We are thrilled to share our recent article in @PsychTimes highlighting the clinical development of RE104, a proprietary, serotonergic #psychedelic drug candidate for underserved #mentalhealth disorders, beginning with #postpartumdepression: https://t.co/YQieaUXPAC

[Reunion Neuroscience @ReunionNeuro]

We’re excited to announce the publication of the results of preclinical studies in ACS Chemical Neuroscience demonstrating the potential of RE104 for development in depressive disorders. Learn more: https://t.co/rXQs3fTqmK

@ACSPublications
#mentalhealthdisorders
#PPD

[Reunion Neuroscience @ReunionNeuro]

Mental health conditions are the leading underlying cause of pregnancy-related death. In our mission to address the worldwide mental health crisis, we're advancing RE104 for underserved #mentalhealth disorders, beginning with #postpartumdepression. #MaternalMentalHealth

[Reunion Neuroscience @ReunionNeuro]

We are proud to recognize #MMHWeek2024. Our team is passionate about supporting the #postpartumdepression community as we advance RE104, our proprietary, clinical-stage serotonergic #psychedelic drug candidate for underserved #mentalhealth disorders, beginning with #PPD.

[Reunion Neuroscience @ReunionNeuro]

We’re excited to announce the closing of our $103M Series A financing co-led by @MPMCapital and @novoholdings. This will support the RECONNECT Phase 2 clinical trial for RE104 in #PPD and expansion into other psychiatric indications. Learn more: https://t.co/ZTbkud5nVw

[Reunion Neuroscience @ReunionNeuro]

We’re excited to announce that the clinical dataset from our Phase 1 study of lead asset, RE104, will be presented in both a podium and poster at the @ADAA_Anxiety 2024 Conference taking place April 11-14. Learn more: https://t.co/pBwF2aq8fF

#PPD
#ADAA2024

[Reunion Neuroscience @ReunionNeuro]

Breaking: Reunion has entered into a definitive arrangement agreement with @MPMCapital, a world-leading #biotech #investment firm, whereby MPM affiliates would acquire Reunion in an all-cash transaction valued at approximately $13.1 million. Full story: https://t.co/BXq6JzjcgC

[Reunion Neuroscience @ReunionNeuro]

#DYK? When communities invest in women, they reinvest up to 90% of their earnings back into their families & the ripple effects reach far beyond the individual. Today, we celebrate International Day of Action on Women's Health as we pioneer the future of #womenshealth together.

[Reunion Neuroscience @ReunionNeuro]

Our CSO, Nathan Bryson, joined @The_GreenRush podcast this week to share details on his journey with Reunion, our unique serotonergic #psychedelic compound developed to treat #postpartumdepression, Company goals and more. Tune in for the episode: https://t.co/4hN46FNJv2 $REUN